Sale!

KRAS and NRAS Mutation Analysis Panel Test Cost

Original price was: 2,860 د.إ.Current price is: 2,570 د.إ.

-10%

The KRAS and NRAS Mutation Analysis Panel Test is a comprehensive diagnostic tool used to identify mutations in the KRAS and NRAS genes. These genes play a crucial role in the regulation of cell division, and mutations in them are often associated with the development of various types of cancer, including colorectal, lung, and pancreatic cancers. By analyzing these mutations, healthcare professionals can gain valuable insights into the nature of a patient’s cancer, which can significantly influence treatment decisions and prognostic assessments.

Performed at DNA Labs UAE, a leading facility in genetic testing, this panel test employs advanced molecular techniques to ensure high accuracy and reliability. The cost of the test is set at 2570 AED, reflecting the sophisticated technology and expertise required to conduct this analysis. Results from the KRAS and NRAS Mutation Analysis Panel Test can help in determining the suitability of certain targeted therapies, making it an essential component in the personalized medicine approach to cancer treatment. This test is particularly recommended for patients diagnosed with cancers that are known to be associated with KRAS and NRAS mutations, providing a critical step towards optimized treatment planning.

Description

KRAS and NRAS Mutation Analysis Panel Test

Test Cost: AED 2570.0

Symptoms and Diagnosis

The KRAS and NRAS Mutation Analysis Panel test is a molecular diagnostic test that detects specific mutations in the KRAS and NRAS genes. These genes are commonly mutated in various types of cancer, including colorectal cancer, lung cancer, and melanoma. The test analyzes the DNA from a patient’s tumor sample to identify mutations in the KRAS and NRAS genes. The presence of these mutations can provide important information about the prognosis of the cancer and can help guide treatment decisions.

Test Components

Price: AED 2570.0
Sample Condition: Submit formalin fixed paraffin embedded tissue block. Ship at room temperature. Block should have at least 10% tumor tissue.
Duly filled NGS Test Requisition Form is mandatory.

Report Delivery

Sample: Tuesday by 11 am

Report: Monday

Method

PCR, Fragment analysis, and Sequencing

Test Type

Cancer

Doctor

Oncologist

Test Department

Molecular Diagnostics

Pre Test Information

Duly filled NGS Test Requisition Form is mandatory.

Test Details

The KRAS & NRAS Mutation Analysis Panel test is typically performed on patients with advanced or metastatic cancer, as these mutations are more commonly found in these stages of the disease. The test can help determine if a patient is eligible for targeted therapies that specifically target the mutated KRAS or NRAS proteins. Overall, the KRAS & NRAS Mutation Analysis Panel test is an important tool in personalized medicine, as it helps tailor treatment options to individual patients based on their specific genetic mutations.

Test Name	KRAS and NRAS MUTATION ANALYSIS PANEL Test
Components
Price	2570.0 AED
Sample Condition	Submit formalin fixed paraffin embedded tissue block. Ship at room temperature. Block should have at least 10% tumor tissue. Duly filled NGS Test Requisition Formis mandatory.
Report Delivery	Sample Tue by 11 am; Report Mon
Method	PCR, Fragment analysis and Sequencing
Test type	Cancer
Doctor	Oncologist
Test Department:	MOLECULAR DIAGNOSTICS
Pre Test Information	Duly filled NGS Test Requisition Formis mandatory.
Test Details	The KRAS & NRAS Mutation Analysis Panel test is a molecular diagnostic test that detects specific mutations in the KRAS and NRAS genes. These genes are commonly mutated in various types of cancer, including colorectal cancer, lung cancer, and melanoma. The test analyzes the DNA from a patient’s tumor sample to identify mutations in the KRAS and NRAS genes. The presence of these mutations can provide important information about the prognosis of the cancer and can help guide treatment decisions. The KRAS & NRAS Mutation Analysis Panel test is typically performed on patients with advanced or metastatic cancer, as these mutations are more commonly found in these stages of the disease. The test can help determine if a patient is eligible for targeted therapies that specifically target the mutated KRAS or NRAS proteins. Overall, the KRAS & NRAS Mutation Analysis Panel test is an important tool in personalized medicine, as it helps tailor treatment options to individual patients based on their specific genetic mutations.